Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Prodrugs01:30

Prodrugs

4.4K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
4.4K
Pneumonia IV: Management01:28

Pneumonia IV: Management

835
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
835
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

553
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
553
Diversity of Archaea IV01:29

Diversity of Archaea IV

495
Hyperthermophilic archaea are a group of extremophiles thriving at temperatures above 80°C, often in hydrothermal vents and volcanic soils where conditions surpass the boiling point of water. At such temperatures, proteins, membranes, and DNA in most organisms degrade, but hyperthermophiles have evolved remarkable adaptations to maintain stability and function.Unique Cellular FeaturesHyperthermophilic membranes are composed of a monolayer of biphytanyl tetraether lipids, which resist...
495
Angina IV: Management01:26

Angina IV: Management

308
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
308
Diversity of Protists IV01:27

Diversity of Protists IV

1.1K
Amoebozoa represent a diverse group of terrestrial and aquatic protists that utilize lobe-shaped pseudopodia for locomotion and feeding. This characteristic differentiates them from the Rhizaria, which possess threadlike pseudopodia. The primary classifications within Amoebozoa include gymnamoebas, entamoebas, and the plasmodial and cellular slime molds. Phylogenetic evidence indicates that Amoebozoa diverged from a lineage that ultimately gave rise to fungi and animals.Gymnamoebas and...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic mapping reveals cisplatin disruption of protein phosphorylation signalling genome-wide.

Metallomics : integrated biometal science·2026
Same author

In Vivo Imaging of a Photoactivatable Platinum Prodrug by Metal-Centered Radiolabeling.

Journal of the American Chemical Society·2026
Same author

Ultra-small luminescent copper nanocluster-catalyzed C-S cross coupling reactions: the effect of ligand substituents in modulating catalytic efficiency.

Nanoscale·2026
Same author

A Correlative X‑ray Bioimaging Triad for Metals in Biomedical Research.

Chemical & biomedical imaging·2026
Same author

In Situ Lipid Interactions of an Anticancer Metal Complex.

Inorganic chemistry·2026
Same author

Photoswitchable Small Molecules for Cancer Therapeutics: Mechanisms, Advances, and Challenges.

Chemistry, an Asian journal·2026
Same journal

Zinc Fingers.

Metal ions in life sciences·2020
Same journal

Nickel, Iron, Sulfur Sites.

Metal ions in life sciences·2020
Same journal

The Siroheme-[4Fe-4S] Coupled Center.

Metal ions in life sciences·2020
Same journal

Molybdenum and Tungsten Cofactors and the Reactions They Catalyze.

Metal ions in life sciences·2020
Same journal

The Cofactors of Nitrogenases.

Metal ions in life sciences·2020
Same journal

Basic Iron-Sulfur Centers.

Metal ions in life sciences·2020
See all related articles

Related Experiment Video

Updated: Feb 15, 2026

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.6K

Platinum(IV) Prodrugs.

V Venkatesh, Peter J Sadler

    Metal Ions in Life Sciences
    |February 3, 2018
    PubMed
    Summary
    This summary is machine-generated.

    Platinum(IV) (Pt(IV)) prodrugs offer a promising approach for cancer therapy. These prodrugs are activated within cancer cells, releasing active platinum(II) agents and potentially delivering synergistic molecules for improved treatment outcomes.

    More Related Videos

    Electrochemical Roughening of Thin-Film Platinum Macro and Microelectrodes
    08:32

    Electrochemical Roughening of Thin-Film Platinum Macro and Microelectrodes

    Published on: June 30, 2019

    8.3K
    Synthesis of Platinum-nickel Nanowires and Optimization for Oxygen Reduction Performance
    09:02

    Synthesis of Platinum-nickel Nanowires and Optimization for Oxygen Reduction Performance

    Published on: April 27, 2018

    8.3K

    Related Experiment Videos

    Last Updated: Feb 15, 2026

    Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
    08:54

    Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

    Published on: February 17, 2023

    1.6K
    Electrochemical Roughening of Thin-Film Platinum Macro and Microelectrodes
    08:32

    Electrochemical Roughening of Thin-Film Platinum Macro and Microelectrodes

    Published on: June 30, 2019

    8.3K
    Synthesis of Platinum-nickel Nanowires and Optimization for Oxygen Reduction Performance
    09:02

    Synthesis of Platinum-nickel Nanowires and Optimization for Oxygen Reduction Performance

    Published on: April 27, 2018

    8.3K

    Area of Science:

    • Inorganic Chemistry
    • Medicinal Chemistry
    • Cancer Therapeutics

    Background:

    • Platinum(IV) prodrugs are kinetically inert octahedral complexes.
    • They can be activated in cancer cells via reduction to active platinum(II) species.
    • This activation can be triggered by intracellular reducing agents or photoexcitation.

    Purpose of the Study:

    • To provide an overview of recent advancements in the design of Pt(IV) prodrugs.
    • To highlight the potential of Pt(IV) prodrugs in cancer treatment.
    • To discuss the versatility of Pt(IV) prodrugs for drug delivery and targeting.

    Main Methods:

    • Review of recent literature on Pt(IV) prodrug design and development.
    • Analysis of the mechanisms of Pt(IV) prodrug activation.
    • Exploration of strategies for functionalizing Pt(IV) complexes.

    Main Results:

    • Pt(IV) prodrugs can be selectively reduced to active Pt(II) complexes within cancer cells.
    • Axial ligands on Pt(IV) complexes can be functionalized for synergistic therapy, targeting, or delivery.
    • Functionalized Pt(IV) prodrugs show promise for enhanced efficacy and reduced side effects.

    Conclusions:

    • Pt(IV) prodrugs represent a promising class of anticancer agents with potential for improved therapeutic profiles.
    • The ability to incorporate diverse functionalities offers opportunities for tailored cancer treatments.
    • Further clinical development is warranted to realize the full potential of Pt(IV) prodrugs.